Novartis Finishes Up $51.6B Alcon Purchase

Law360, New York (December 15, 2010, 1:49 PM EST) -- Swiss drug giant Novartis AG wrested full control of eye care company Alcon Inc. on Wednesday after almost a year of regulatory and shareholder battles in the $51.6 billion deal.

To complete the long-awaited takeover, Novartis will buy Alcon's remaining stock for $12.9 billion, or $168 per share. In January, Novartis paid about $38.7 billion for 77 percent of the company in a deal with Nestle SA.

"The full merger is the logical conclusion of our initial strategic investment in Alcon," Dr. Daniel Vasella, chairman and...
To view the full article, register now.